Attached files
| file | filename |
|---|---|
| 10-Q - 10-Q - Turning Point Therapeutics, Inc. | tptx-10q_20210331.htm |
| EX-32.1 - EX-32.1 - Turning Point Therapeutics, Inc. | tptx-ex321_8.htm |
| EX-31.2 - EX-31.2 - Turning Point Therapeutics, Inc. | tptx-ex312_7.htm |
| EX-31.1 - EX-31.1 - Turning Point Therapeutics, Inc. | tptx-ex311_6.htm |
| EX-10.3 - EX-10.3 - Turning Point Therapeutics, Inc. | tptx-ex103_12.htm |
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Turning Point Therapeutics, Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
|
|
(1) |
The Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended; and |
|
|
(2) |
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
|
Date: May 5, 2021 |
|
By: |
/s/ Brian Baker |
|
|
|
|
Brian Baker |
|
|
|
|
Senior Vice President of Finance & Administration (Principal Financial and Accounting Officer) |
This certification accompanies the Report to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Report), irrespective of any general incorporation language contained in such filing.